Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20,556 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Genotype-environment interaction on arterial stiffness: A pedigree-based study].
Wang XH, Wang SY, Peng HX, Fan M, Guo HD, Hou TJ, Wang MY, Wu YQ, Qin XY, Tang X, Li J, Chen DF, Hu YH, Wu T. Wang XH, et al. Among authors: wu t, wu yq. Beijing Da Xue Xue Bao Yi Xue Ban. 2023 Jun 18;55(3):400-407. doi: 10.19723/j.issn.1671-167X.2023.03.003. Beijing Da Xue Xue Bao Yi Xue Ban. 2023. PMID: 37291913 Free PMC article. Chinese.
Multicentre, cross-sectional surveillance of Helicobacter pylori prevalence and antibiotic resistance to clarithromycin and levofloxacin in urban China using the string test coupled with quantitative PCR.
Wang L, Li Z, Tay CY, Marshall BJ, Gu B; Guangdong Center for Quality Control of Clinical Gene Testing and Study Group of Chinese Helicobacter pylori Infection and Antibiotic Resistance Rates Mapping Project (CHINAR-MAP). Wang L, et al. Lancet Microbe. 2024 Jun;5(6):e512-e513. doi: 10.1016/S2666-5247(24)00027-2. Epub 2024 Mar 2. Lancet Microbe. 2024. PMID: 38437848 Free article. No abstract available.
Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): A single-arm, phase II study.
Meng X, Wang J, Xia J, Wu T, Luo Z, Hong Y, Lu P, Guo Y, Ji Y, Zhang M, Yang L, Cheng P, Liang W, Shan Z, Zhou Y, Wang M, Lu T, Song M, Zong H, Song L, Wang W, Guan L, Li Y, Xing J, Xing S, Wu H, Chu J, Luo X, Lu Y, Xin D, Li A, Jiang B, Li S, Jiang G, Fan Q, Zhao F, Zheng R, Zhu W, Hou Z, Jia Y, Wang F. Meng X, et al. Among authors: wu h, wu t. Eur J Cancer. 2024 Nov;212:114328. doi: 10.1016/j.ejca.2024.114328. Epub 2024 Sep 12. Eur J Cancer. 2024. PMID: 39307038 Clinical Trial.
20,556 results
You have reached the last available page of results. Please see the User Guide for more information.